

Luitpold Pharmaceuticals, Inc. US Research Payments Report
January 1, 2015 through December 31, 2015

Payee	Study Name	Principal Investigator / Lead Researcher Last Name	Principal Investigator / Lead Researcher First Name	City of PI / Lead Researcher	State of PI / Lead Researcher	Total
ACHIEVE CLINICAL RESEARCH LLC	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	WILLIAMS	HAYES	BIRMINGHAM	AL	\$8,186.20
ADOBE CLINICAL RESEARCH, LLC	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	MOUSSA	SAM	TUCSON	AZ	\$8,897.68
AKDHC MEDICAL RESEARCH SERVICE	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	CORTEZ	ANDREW	AVONDALE	AZ	\$25,796.54
AKDHC MEDICAL RESEARCH SERVICE	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	FADIA	AMIT	TUCSON	AZ	\$16,696.54
AKDHC MEDICAL RESEARCH SERVICE	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	HACHEM	HASSAN	MESA	AZ	\$1,558.30
AKDHC MEDICAL RESEARCH SERVICE	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	MUSTAFA	ESMAT	PHOENIX	AZ	\$26,746.54
AKDHC MEDICAL RESEARCH SERVICE	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	NICA	ROMANITA	PRESCOTT	AZ	\$8,606.64
AKDHC MEDICAL RESEARCH SERVICE	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	QURESHI	JUNAID	PHOENIX	AZ	\$18,046.54
AKDHC MEDICAL RESEARCH SERVICE	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	SANTOS	PETER	GLENDALE	AZ	\$19,835.54
AKRON NEPHROLOGY ASSOCIATES	A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF SODIUM THIOSULFATE FOR THE TREATMENT OF PAIN ASSOCIATED WITH CALCIFIC UREMIC ARTERIOLOPATHY FOLLOWED BY A SINGLE ARMED EXTENSION PHASE TO PROSPECTIVELY OBSERVE LESION PROGRESSION IN THE PRESENCE OF SODIUM THIOSULFATE TREATMENT	RAINA	RUPESH	AKRON	OH	\$792.81
ALFRED I DUPONT HOSP FOR CHILDREN	A MULTICENTER REGISTRY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF MAINTENANCE TREATMENT WITH IRON SUCROSE (VENOFER) IN PEDIATRIC PATIENTS BETWEEN 2 AND 17 YEARS WITH CHRONIC KIDNEY DISEASE	ZARITSKY	JOSHUA	WILMINGTON	DE	\$1,400.00
ANTIETAM ONCOLOGY AND HEMATOLOGY	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	HAMDAN	HIND	HAGERSTOWN	MD	\$32,938.54
ASA CLINICAL RESEARCH LLC	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	RABIEI	ABBAS	JUPITER	FL	\$5,321.54
ASHEVILLE GASTROENTEROLOGY ASSOCIATES, PA	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	HARLAN	WILLIAM	ASHEVILLE	NC	\$9,821.20
ASHLAND-BELLFONTE CANCER CENTER	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	JAIN	KIRTI	ASHLAND	KY	\$1,611.54
ASSOCIATES ON ONCOLOGY AND HEMATOLOGY	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	GANDHI	JITENDRA	CHATTANOOGA	TN	\$11,877.84
ASSOCIATES ON ONCOLOGY AND HEMATOLOGY	OBSERVATIONAL STUDY ON THE USE OF IV IRON THERAPY AMONG SUBJECTS WITH IRON DEFICIENCY ANEMIA	GANDHI	JITENDRA	CHATTANOOGA	TN	\$500.00
ATLANTA GASTROENTEROLOGY ASSOCIATES LLC	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	WOLF	DOUGLAS	ATLANTA	GA	\$30,058.70
ATLANTA GASTROENTEROLOGY SPECIALISTS PC	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	SALZBERG	BRUCE	SUWANEE	GA	\$28,673.20
ATLANTA VANGUARD MEDICAL ASSOCIATES	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	VARGAS MORRIS	FAYE	SMYRNA	GA	\$187.08
BASSETT MEDICAL CENTER	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	FREETH	AMY	COOPERSTOWN	NY	\$3,905.00
BLOOD AND CANCER CETNER OF EAST TEXAS	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	GROSS	GARY	TYLER	TX	\$1,071.54
BOND CLINIC, PA	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	HLALAH	OSAMA	WINTER HAVEN	FL	\$1,821.54
BRISTOL HOSPITAL, INC.	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	ZAKKO	SALAM	BRISTOL	CT	\$8,661.20

Luitpold Pharmaceuticals, Inc. US Research Payments Report
January 1, 2015 through December 31, 2015

Payee	Study Name	Principal Investigator / Lead Researcher Last Name	Principal Investigator / Lead Researcher First Name	City of PI / Lead Researcher	State of PI / Lead Researcher	Total
BROOKDALE HOSPITAL MEDICAL CENTER	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	WANG	JEN	BROOKLYN	NY	\$17,825.00
BROWARD HEALTH MEDICAL CENTER	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	MAINI	ARCHANA	FT LAUDERDALE	FL	\$1,713.50
CANCER CARE CENTERS OF BREVARD	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	ROSS	DAVID	ROCKLEDGE	FL	\$260.10
CANCER CARE CENTERS OF BREVARD	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	TAHN	CARL	ROCKLEDGE	FL	\$2,053.54
CANCER CARE OF NORTH FLORIDA, PA	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	KHAN	WASEEM	LAKE CITY	FL	\$8,365.29
CANCER CENTER OF CENTRAL CONNECTICUT	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	BYEFF	PETER	SOUTHINGTON	CT	\$2,900.54
CEDARS-SINAI MEDICAL CENTER	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	MELMED	GIL	LOS ANGELES	CA	\$7,721.25
CENTER FOR ADVANCED GASTROENTEROLOGY	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	HILAL	RAOUF	MAITLAND	FL	\$1,287.54
CENTER FOR CANCER AND BLOOD DISORDERS	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	BOCCIA	RALPH	BETHESDA	MD	\$68,361.44
CENTRAL TEXAS MEDICAL SPECIALISTS, PLLC	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	DOWNIE	BENJAMIN	AUSTIN	TX	\$6,527.00
CHARLESTONE HEMATOLOGY ONCOLOGY ASSOCIATES, PA	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	ORCUTT	JAMES	CHARLESTON	SC	\$967.00
CHARLOTTE GASTROENTEROLOGY AND HEPTALOGY, PLLC	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	WILSON	JASON	CHARLOTTE	NC	\$567.00
CHEVY CHASE CLINICAL RESEARCH	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	HARDI	ROBERT	CHEVY CHASE	MD	\$10,672.68
CHEYENNE REGIONAL MEDICAL CENTER	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	WORKMAN	NATALIE	CHEYENNE	WY	\$1,501.54
CHI ST VINCENT MEDICAL CENTER	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	CLEVELAND	LYNN	HOT SPRINGS	AR	\$260.10
CHILDRENS HOSPITAL MEDICAL CENTER	A MULTICENTER REGISTRY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF MAINTENANCE TREATMENT WITH IRON SUCROSE (VENOFER) IN PEDIATRIC PATIENTS BETWEEN 2 AND 17 YEARS WITH CHRONIC KIDNEY DISEASE	VANDEVOORDE	RENE	CINCINNATI	OH	\$2,200.00
CLEVELAND CLINIC HOSPITAL	A MULTICENTER REGISTRY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF MAINTENANCE TREATMENT WITH IRON SUCROSE (VENOFER) IN PEDIATRIC PATIENTS BETWEEN 2 AND 17 YEARS WITH CHRONIC KIDNEY DISEASE	DELL	KATHERINE	CLEVELAND	OH	\$800.00
CLINICAL RESEARCH CONSULTANTS, LLC	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	AWAD	AHMED	KANSAS CITY	MO	\$43,540.50
CLINICAL RESEARCH SOLUTIONS LLC	A BLINDED RANDOMIZED PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF INJECTAFER IN THE TREATMENT OF IRON DEFICIENT PATIENTS WITH FIBROMYALGIA	BOOMERSHINE	CHAD	MIDDLEBURG HEIGHTS	OH	\$345,464.10
COMMONWEALTH CLINICAL STUDIES	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	STERN	JERRY	BROCKTON	MA	\$520.20
COMPREHENSIVE CANCER CARE CLINIC	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	KHOJASTEH	ALI	JEFFERSON CITY	MO	\$93.54
CONSULTANTS FOR CLINICAL RESEARCH	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	CHOKSHI	MANISH	CINCINNATI	OH	\$36,049.04
DANA-FARBER CANCER INSTITUTE	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	OKAM	MAUREEN	BOSTON	MA	\$19,242.00
DAYTON GASTROENTEROLOGY, INC.	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	STONE	LISA	BEAVERCREEK	OH	\$1,123.20
DELAWARE VALLEY NEPHROLOGY	A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF SODIUM THIOSULFATE FOR THE TREATMENT OF PAIN ASSOCIATED WITH CALCIFIC UREMIC ARTERIOLOPATHY FOLLOWED BY A SINGLE ARMED EXTENSION PHASE TO PROSPECTIVELY OBSERVE LESION PROGRESSION IN THE PRESENCE OF SODIUM THIOSULFATE TREATMENT	JONES	EDWARD	PHILADELPHIA	PA	\$4,827.73

Luitpold Pharmaceuticals, Inc. US Research Payments Report
January 1, 2015 through December 31, 2015

Payee	Study Name	Principal Investigator / Lead Researcher Last Name	Principal Investigator / Lead Researcher First Name	City of PI / Lead Researcher	State of PI / Lead Researcher	Total
DELTA ONCOLOGY ASSOCIATES	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPcidIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	SHABAZZ	LLOYD	PORTSMOUTH	VA	\$5,896.54
DIGESTIVE AND LIVER DISEASE SPECIALISTS	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOS) VS. ORAL IRON TO BASELINE HEPcidIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	WOOTTON	TAYLOR	NORFOLK	VA	\$22,913.20
DIGESTIVE CARE PHYSICIANS	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOS) VS. ORAL IRON TO BASELINE HEPcidIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	RASHBAUM	STEPHEN	JOHNS CREEK	GA	\$260.10
DIGESTIVE HEALTH SPECIALISTS OF SOUTHEAST	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOS) VS. ORAL IRON TO BASELINE HEPcidIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	RUTLAND	TRAVIS	DOTHAN	AL	\$34,323.20
DOCTORS RESEARCH INSTITUTE INC	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPcidIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	GONZALEZ	MISAEI	MIAMI	FL	\$2,185.08
DOYLE, NATALIE	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPcidIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	DOYLE	NATALIE	WILSON	NC	\$17,410.08
DREXEL UNIVERSITY COLLEGE OF MEDICINE	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPcidIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	STYLER	MICHAEL	PHILADELPHIA	PA	\$7,929.14
EASTCHESTER CENTER FOR CANCER CARE	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPcidIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	VOLTERRA	FABIO	BRONX	NY	\$6,828.00
EASTERN INSTITUTE OF MEDICAL SCIENCES PLLC	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPcidIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	BURKE	LILLIAN	GREENVILLE	NC	\$5,198.64
EASTERN NEPHROLOGY ASSOCIATES	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPcidIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	MONTERO	MANUEL	NEW BERN	NC	\$9,606.54
EL PORTAL CANCER INSTITUTE	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPcidIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	MALIK	IMTIAZ	MERCED	CA	\$13,803.54
ENDOSCOPIC MICROSURGERY ASSOCIATES, PA	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOS) VS. ORAL IRON TO BASELINE HEPcidIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	NOAR	MARK	TOWSON	MD	\$3,060.70
FLORIDA HEALTH CENTER RESEARCH	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPcidIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	GERSHENBAUM	BART	FT LAUDERDALE	FL	\$9,271.54
FLORIDA MEDICAL CLINIC, PA	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPcidIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	MCDONOUGH	RICHARD	ZEPHYRHILLS	FL	\$2,171.54
GABRAIL CANCER CENTER RESEARCH	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPcidIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	GABRAIL	NASHAT	CANTON	OH	\$3,693.54
GASTRO CENTER OF MARYLAND	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOS) VS. ORAL IRON TO BASELINE HEPcidIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	RAI	RUDRAJIT	COLUMBIA	MD	\$927.00
GASTROENTEROLOGY GROUP OF NAPLES	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOS) VS. ORAL IRON TO BASELINE HEPcidIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	PHILLIPS	RAYMOND	NAPLES	FL	\$4,090.20
GASTROENTEROLOGY ASSOCIATES CLINICAL RESEARCH	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOS) VS. ORAL IRON TO BASELINE HEPcidIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	HOMOKY	DOUGLAS	KINGSPORT	TN	\$1,192.00
GASTROENTEROLOGY ASSOCIATES OF CENTRAL GEORGIA	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOS) VS. ORAL IRON TO BASELINE HEPcidIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	SEDGHI	SHAHRIAR	MACON	GA	\$1,123.20
GASTROENTEROLOGY LTD.	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOS) VS. ORAL IRON TO BASELINE HEPcidIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	STOCKWELL	DAVID	VIRGINIA BEACH	VA	\$12,177.10
GASTROENTEROLOGY RESEARCH OF LIMA	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOS) VS. ORAL IRON TO BASELINE HEPcidIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	RINESMITH	SCOTT	LIMA	OH	\$5,613.20
GASTROENTEROLOGY RESEARCH OF SAN ANTONIO	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOS) VS. ORAL IRON TO BASELINE HEPcidIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	RANDALL	CHARLES	SAN ANTONIO	TX	\$30,536.48
GASTROENTEROLOGY RESEARCH OF THE BAY AREA	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOS) VS. ORAL IRON TO BASELINE HEPcidIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	STOLLMAN	NEIL	OAKLAND	CA	\$260.10
GASTROENTEROLOGY RESEARCH OF TUCSON	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOS) VS. ORAL IRON TO BASELINE HEPcidIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	CONTRERAS	BRYAN	TUCSON	AZ	\$27,366.28
GETTYSBURG CANCER CENTER	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPcidIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	SHAH	SATISH	GETTYSBURG	PA	\$12,331.54

Luitpold Pharmaceuticals, Inc. US Research Payments Report
January 1, 2015 through December 31, 2015

Payee	Study Name	Principal Investigator / Lead Researcher Last Name	Principal Investigator / Lead Researcher First Name	City of PI / Lead Researcher	State of PI / Lead Researcher	Total
GLENDALE MEMORIAL HOSPITAL	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	UCAR	KALUST	GLENDALE	CA	\$3,500.00
GLOBAL CANCER RESEARCH INSTITUTE	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	BUI	LYNNE	GILROY	CA	\$93.54
GREAT FALLS CLINIC, LLP	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	GUTER	KARL	GREAT FALLS	MT	\$12,678.74
GREAT LAKES GASTROENTEROLOGY RESEARCH	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	FRIEDENBERG	KEITH	MENTOR	OH	\$7,573.20
HEALING HANDS ONCOLOGY AND MEDICAL CARE	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	ATTOH	MICHAEL	LAWDALE	CA	\$21,510.00
HEALING HANDS ONCOLOGY AND MEDICAL CARE	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	WALLACE	OLUKEMI	LAWDALE	CA	\$1,911.54
HEMATOLOGY AND ONCOLOGY ASSOCIATES, INC.	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	HAUT	MITCHELL	CANTON	OH	\$10,981.54
HEMATOLOGY ONCOLOGY CLINIC	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	CASTINE	MICHAEL	BATON ROUGE	LA	\$18,156.54
HENRY FORD HOSPITAL	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	KURIAKOSE	PHILIP	DETROIT	MI	\$11,255.00
HOPE MEDICAL RESEARCH, INC	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	MOQUETE	MARIO	KISSIMMEE	FL	\$3,185.00
HOPE MEDICAL RESEARCH, INC	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	TABREZ	SHAMS	KISSIMMEE	FL	\$5,845.08
ILLINOIS CANCER SPECIALISTS	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	MALHOTRA	RAJAT	ARLINGTON HEIGHTS	IL	\$5,466.54
INFUSION ASSOCIATES, PC	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	NEDD	KHAN	GRAND RAPIDS	MI	\$23,592.00
IRONWOOD PHYSICIANS PC	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	KALMADI	SUJITH	CHANDLER	AZ	\$3,109.54
IRONWOOD PHYSICIANS PC	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	SHTIVELBAND	MIKHAIL	CHANDLER	AZ	\$3,211.54
JOHN B ARCHBOLD MEMORIAL HOSPITAL	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	COLEMAN	TERESA	THOMASVILLE	GA	\$5,621.54
JOHNS HOPKINS UNIVERSITY	A MULTICENTER REGISTRY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF MAINTENANCE TREATMENT WITH IRON SUCROSE (VENOFER) IN PEDIATRIC PATIENTS BETWEEN 2 AND 17 YEARS WITH CHRONIC KIDNEY DISEASE	NEU	ALICIA	BALTIMORE	MD	\$2,800.00
JOHNS HOPKINS UNIVERSITY	A PLACEBO-CONTROLLED DOUBLE-BLIND CROSSOVER STUDY TO EVALUATE THE EFFICACY OF KETOROLAC NASAL SPRAY (SPRIX) AS COMPARED TO SUMATRIPTAN NASAL SPRAY AND PLACEBO FOR THE ACUTE ABORTIVE TREATMENT OF MIGRAINE ATTACKS	PETERLIN	BARBARA	BALTIMORE	MD	\$28,625.00
JOLIET ONCOLOGY HEMATOLOGY ASSOCIATES	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	SIVARAJAN	KULUMANI	JOLIET	IL	\$59,732.89
JONES CLINIC PC	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	JONES	CLYDE	GERMANTOWN	TN	\$1,110.54
JONES CLINIC PC	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	JONES	CLYDE	GERMANTOWN	TN	\$8,100.00
KINSTON MEDICAL SPECIALISTS PA	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	MARILLEY	MARK	KINSTON	NC	\$34,046.54
KINSTON MEDICAL SPECIALISTS PA	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	MARILLEY	MARK	KINSTON	NC	\$1,442.25
KOSAIR CHILDREN'S HOSPITAL MATERNAL FETAL MEDICINE SPECIALISTS	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	HOW	HELEN	LOUISVILLE	KY	\$12,970.00

Luitpold Pharmaceuticals, Inc. US Research Payments Report
January 1, 2015 through December 31, 2015

Payee	Study Name	Principal Investigator / Lead Researcher Last Name	Principal Investigator / Lead Researcher First Name	City of PI / Lead Researcher	State of PI / Lead Researcher	Total
LAFAYETTE GENERAL MEDICAL CENTER	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	ARTERBURN	JAMES	LAFAYETTE	LA	\$1,452.10
LAKE RESEARCH, LLC	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	ROMAN	ELOY	MIAMI LAKES	FL	\$843.54
LANCASTER CANCER CENTER LTD	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	DEGREEN	HYATT	LANCASTER	PA	\$3,058.54
LOMA LINDA UNIVERSITY ADVENTIST HEALTH SCIENCES CENTER	A HISTOMORPHOMETRIC ANALYSIS OF BONE FORMATION WITH THREE DIFFERENT BONE GRAFT MATERIALS FOLLOWING SINUS AUGMENTATION	KAN	JOSEPH	LOMA LINDA	CA	\$29,965.00
LOUISIANA RESEARCH CENTER LLC	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	JOHNSON	LAWRENCE	SHREVEPORT	LA	\$18,859.10
MARY HITCHCOCK MEMORIAL HOSP	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	SIEGEL	COREY	LEBANON	NH	\$45,632.25
MEDICAL RESEARCH CENTER OF CONNECTICUT	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	GINSBURG	PHILIP	HAMDEN	CT	\$11,177.20
MEMORIAL CLINICAL RESEARCH	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	BARRETO	ANGELIQUE	OKLAHOMA CITY	OK	\$9,893.04
MERCY CLINIC, INC.	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	KOTA	MANJUSHA	HOT SPRINGS	AR	\$93.54
MONTEFIORE MEDICAL CENTER	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	CHAITOWITZ	MARK	BRONX	NY	\$14,275.00
NEPHROLOGY AND HYPERTENSION ASSOCIATES OF NJ	A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF SODIUM THIOSULFATE FOR THE TREATMENT OF PAIN ASSOCIATED WITH CALCIFIC UREMIC ARTERIOLOPATHY FOLLOWED BY A SINGLE ARMED EXTENSION PHASE TO PROSPECTIVELY OBSERVE LESION PROGRESSION IN THE PRESENCE OF SODIUM THIOSULFATE TREATMENT	PITONE	JOSEPH	VOORHEES	NJ	\$780.75
NEPHROLOGY ASSOCIATES OF NORTHERN INDIANA	A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF SODIUM THIOSULFATE FOR THE TREATMENT OF PAIN ASSOCIATED WITH CALCIFIC UREMIC ARTERIOLOPATHY FOLLOWED BY A SINGLE ARMED EXTENSION PHASE TO PROSPECTIVELY OBSERVE LESION PROGRESSION IN THE PRESENCE OF SODIUM THIOSULFATE TREATMENT	OSHAUGHNESSY	ANDREW	FT WAYNE	IN	\$5,333.84
NEPHROLOGY CONSULTANTS, LLC	A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF SODIUM THIOSULFATE FOR THE TREATMENT OF PAIN ASSOCIATED WITH CALCIFIC UREMIC ARTERIOLOPATHY FOLLOWED BY A SINGLE ARMED EXTENSION PHASE TO PROSPECTIVELY OBSERVE LESION PROGRESSION IN THE PRESENCE OF SODIUM THIOSULFATE TREATMENT	QUADRINI	MICHAEL	HUNTSVILLE	AL	\$6,279.96
NEVINS, MYRON	CLINICAL AND HISTOLOGICAL EVALUATIONS OF OSSIF-EM DEMINERALIZED ALLOGRAFT STRIP FOR ALVEOLAR RIDGE AUGMENTATION PROCEDURES	NEVINS	MYRON	SWAMPSCOTT	MA	\$132,512.00
NORTH MISSISSIPPI HEMATOLOGY AND ONCOLOGY ASSOCIATES	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	CROOT	CHRISTOPHER	TUPELO	MS	\$12,776.54
NORTH MISSISSIPPI HEMATOLOGY AND ONCOLOGY ASSOCIATES	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	HILL	JULIAN	TUPELO	MS	\$260.10
NORTH SHORE HEMATOLOGY ONCOLOGY ASSOCIATES	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	CHU	DAVID	EAST SETAUKET	NY	\$25,436.64
NORTHEAST CLINICAL RESEARCH CENTER, LLC	A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF SODIUM THIOSULFATE FOR THE TREATMENT OF PAIN ASSOCIATED WITH CALCIFIC UREMIC ARTERIOLOPATHY FOLLOWED BY A SINGLE ARMED EXTENSION PHASE TO PROSPECTIVELY OBSERVE LESION PROGRESSION IN THE PRESENCE OF SODIUM THIOSULFATE TREATMENT	KOPYT	NELSON	BETHLEHEM	PA	\$6,482.16
NORTHWEST ALABAMA CANCER CENTER	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	PATEL	HEMANT	MUSCLE SHOALS	AL	\$30,631.54
NORTHWEST GASTROENTEROLOGY ASSOCIATES	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	WOHLMAN	ROBERT	BELLEVUE	WA	\$8,218.20
NORTHWEST GASTROENTEROLOGY CLINIC	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	GALEN	EDWARD	PORTLAND	OR	\$638.10
NYU LANGONE LONG ISLAND CLINICAL RESEARCH ASSOCIATES	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	TEPPER	ROBERT	GREAT NECK	NY	\$16,989.50
OCEAN BLUE MEDICAL RESEARCH CENTER, INC.	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	TERRELONGE	ANTONIO	MIAMI SPRINGS	FL	\$2,133.40
OMEGA RESEARCH CONSULTANTS	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	NAIR	SANTOSH	DEBARY	FL	\$8,381.54
ORCHARD HEALTHCARE RESEARCH INC	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	OLIFF	IRA	SKOKIE	IL	\$1,243.54
OREGON CLINIC PC	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	GRUNKEMEIER	DAVID	PORTLAND	OR	\$18,590.00

Luitpold Pharmaceuticals, Inc. US Research Payments Report
January 1, 2015 through December 31, 2015

Payee	Study Name	Principal Investigator / Lead Researcher Last Name	Principal Investigator / Lead Researcher First Name	City of PI / Lead Researcher	State of PI / Lead Researcher	Total
PACIFIC CANCER MEDICAL CENTER, INC.	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	CHARU	VEENA	ANAHEIM	CA	\$15,073.54
PANDIT, LALITA	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	PANDIT	LALITA	FOUNTAIN VALLEY	CA	\$1,310.04
PASTEUR MEDICAL RESEARCH, PLLC	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	PHO	HOAN	SAN ANTONIO	TX	\$260.10
PHILADELPHIA VA MEDICAL CENTER	PREVALENCE AND TREATMENT OF IRON DEFICIENCY IN ULCERATIVE COLITIS PATIENTS BY SEVERITY OF DISEASE	KHAN	NABEELA	HOUSTON	TX	\$12,000.00
PORTER ADVENTIST HOSPITAL	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	KENNEY	THOMAS	DENVER	CO	\$15,425.00
REGIONAL CANCER CARE ASSOCIATES	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	ZRADA	STEPHEN	CHERRY HILL	NJ	\$1,740.54
RENAL ASSOCIATES OF BATON ROUGE	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	ROPPOLO	MICHAEL	BATON ROUGE	LA	\$4,306.54
SAN ANTONIO GASTROENTEROLOGY ASSOCIATES	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	BULLOCK	JEFF	SAN ANTONIO	TX	\$14,298.60
SANTEE HEMATOLOGY ONCOLOGY INC	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	CLOWNEY	BILLY	SUMTER	SC	\$3,421.54
SHAYE, OMID	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	SHAYE	OMID	WEST HILLS	CA	\$2,123.54
SIOUX LAND HEMATOLOGY-ONCOLOGY ASSOCIATES, LLP	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	WENDER	DONALD	SIOUX CITY	IA	\$12,540.00
SOUTH BAY CENTER FOR GI RESEARCH	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	ZAIDEL	OREN	TORRANCE	CA	\$1,123.20
SOUTH CAROLINA CANCER SPECIALISTS	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	THOMAS	GARY	HILTON HEAD ISLAND	SC	\$4,440.60
SOUTH MISSISSIPPI MEDICAL RESEARCH, LLC	A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF SODIUM THIOSULFATE FOR THE TREATMENT OF PAIN ASSOCIATED WITH CALCIFIC UREMIC ARTERIOLOPATHY FOLLOWED BY A SINGLE ARMED EXTENSION PHASE TO PROSPECTIVELY OBSERVE LESION PROGRESSION IN THE PRESENCE OF SODIUM THIOSULFATE TREATMENT	LANIER	DOUGLAS	GULFPORT	MS	\$567.00
SOUTHEAST MISSOURI HOSPITAL	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	MOSLEY	JAMES	CAPE GIRADEAU	MO	\$7,021.54
SOUTHERN CLINICAL RESEARCH GROUP, LLC	A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF SODIUM THIOSULFATE FOR THE TREATMENT OF PAIN ASSOCIATED WITH CALCIFIC UREMIC ARTERIOLOPATHY FOLLOWED BY A SINGLE ARMED EXTENSION PHASE TO PROSPECTIVELY OBSERVE LESION PROGRESSION IN THE PRESENCE OF SODIUM THIOSULFATE TREATMENT	HOPKINS	ERICA	GULFPORT	LA	\$260.10
ST JOSEPH HERITAGE HEALTHCARE	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	HOLMES	JARROD	SANTA ROSA	CA	\$6,335.54
STANFORD HOSPITAL & CLINICS	A MULTICENTER REGISTRY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF MAINTENANCE TREATMENT WITH IRON SUCROSE (VENOFER) IN PEDIATRIC PATIENTS BETWEEN 2 AND 17 YEARS WITH CHRONIC KIDNEY DISEASE	WONG	CYNTHIA	STANFORD	CA	\$800.00
SYNERGY SAN DIEGO	A DOUBLE-BLIND MULTI-CENTER RANDOMIZED PLACEBO CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF INJECTAFER IN THE TREATMENT OF RESTLESS LEG SYNDROME	BARI	MOHAMMED	NATIONAL CITY	CA	\$2,567.00
TEXAS DIGESTIVE DISEASE CONSULTANTS	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	JAIN	RAJEV	DALLAS	TX	\$1,192.00
TEXAS DIGESTIVE DISEASE CONSULTANTS	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	ITTER	TIMOTHY	SOUTHLAKE	TX	\$1,452.10
THE CENTER FOR GASTROINTESTINAL DISORDERS	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	LAMET	MARK	HOLLYWOOD	FL	\$7,772.68
THE FEINSTEIN INSITUTE FOR MEDICAL RESEARCH	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	SWAMINATH	ARUN	MANHASSET	NY	\$17,278.74
THE GASTROENTEROLOGY GROUP OF SOUTH JERSEY	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	IZANEC	JAMES	VINELAND	NJ	\$359.48
THE OHIO STATE UNIVERSITY HOSPITAL	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	ARSENESCU	RAZVAN	COLUMBUS	OH	\$5,343.00
THE OHIO STATE UNIVERSITY HOSPITAL	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	ZHANG	CHENG	COLUMBUS	OH	\$13,812.00

Luitpold Pharmaceuticals, Inc. US Research Payments Report
January 1, 2015 through December 31, 2015

Payee	Study Name	Principal Investigator / Lead Researcher Last Name	Principal Investigator / Lead Researcher First Name	City of PI / Lead Researcher	State of PI / Lead Researcher	Total
THE PENNSYLVANIA STATE UNIVERSITY	OBSERVATIONAL STUDY ON THE USE OF IV IRON THERAPY AMONG SUBJECTS WITH IRON DEFICIENCY ANEMIA	VERMA	NAVIN	HERSHEY	PA	\$1,250.00
TRI-COUNTY HEMATOLOGY AND ONCOLOGY ASSOCIATES	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	NAGAJOTHI	NAGAPRASAD	MASILLION	OH	\$13,276.54
TRI-STATE GASTROENTEROLOGY ASSOCIATES	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	JONES	MICHAEL	CRESTVIEW HILLS	KY	\$1,123.20
TROY GASTROENTEROLOGY CENTER FOR DIGESTIVE HEALTH	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	WEBER	JOHN	TROY	MI	\$15,005.20
TYLER HEMATOLOGY ONCOLOGY	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	DRODER	ROBERT	TYLER	TX	\$2,178.00
UNIVERSITY OF CONNECTICUT HEALTH CENTER	USE OF RECOMBINANT HUMAN PLATELET-DERIVED GROWTH FACTOR-BB AND SYNTHETIC BETA-TRICALCIUM PHOSPHATE IN INTRAOSSEOUS PERIODONTAL DEFECTS ACCESSED WITH DOUBLE OR SINGLE FLAP APPROACH: A MULTICENTER RANDOMIZED CONTROLLED TRIAL	SCHINCAGLIA	GIAN	FARMINGTON	CT	\$18,332.00
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	ISAACS	KIM	CHAPEL HILL	NC	\$46,325.84
UNIVERSITY CANCER INSTITUTE	IRON CLAD - CAN IRON LESSEN ANEMIA DUE TO CANCER AND CHEMOTHERAPY: A MULTI-CENTER RANDOMIZED DOUBLE-BLIND CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF INJECTAFER	NIEDERMAN	THOMAS	BOYNTON BEACH	FL	\$9,820.54
UNIVERSITY CANCER INSTITUTE	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	THE	ANGELINA	BOYNTON BEACH	FL	\$18,320.00
UNIVERSITY OF COLORADO DENVER	A SINGLE ARM OPEN LABEL STUDY TO COMPARE THE PHARMACOKINETICS SAFETY AND EFFICACY OF SPRIX IN 12 TO 17 YEAR OLD PATIENTS VS. ADULT PATIENTS 18-64 YEARS UNDERGOING OPEN SURGICAL PROCEDURES	CHRISTIANS	UWE	AURORA	CO	\$93,031.88
UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	ALI	TAUSEEF	OKLAHOMA CITY	OK	\$5,100.00
UNIVERSITY OF SOUTHERN ALABAMA	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	CASH	BROOKS	MOBILE	AL	\$14,250.00
WAKE RESEARCH ASSOCIATES WALLACE, STEPHEN	EXTRACTION SOCKET PRESERVATION RIDGE AUGMENTATION	BARISH WALLACE	CHARLES STEPHEN	RALEIGH WILMINGTON	NC NC	\$7,023.20 \$9,514.50
WAVERLY HEMATOLOGY ONCOLOGY	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	KIRBY	SUZANNE	CARY	NC	\$11,543.30
WEST KENTUCKY HEMATOLOGY AND ONCOLOGY GROUP	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	SKINNER	WILLIAM	PADUCAH	KY	\$93.54